General Pharmacology Practice Questions

Q: The enzyme pseudocholinesterase acts on which of the following drugs?

Suxamethonium. **Explanation:** **Correct Answer: D. Suxamethonium** **Mechanism:** Suxamethonium (Succinylcholine) is a depolarizing neuromuscular blocker. Its short duration of action (5–10 minutes) is due to its rapid hydrolysis by **Pseudocholinesterase** (also known as Butyrylcholinesterase or Plasma Cholinesterase), which is synthesized in the liver and found in the plasma. Unlike Acetylcholine, Suxamethonium is not metabolized by Acetylcholinesterase at the motor endplate. **Analysis of Incorrect Options:** * **A. Decamethonium:** Although it is a depolarizing blocker like Suxamethonium, it is not metabolized by cholinesterases; it is excreted unchanged in the urine. * **B. Tubocurarine:** This is a long-acting non-depolarizing blocker. It is primarily excreted in the urine (70%) and bile, and is not metabolized by pseudocholinesterase. * **C. Gallamine:** This is another non-depolarizing blocker that is excreted entirely unchanged by the kidneys. **NEET-PG High-Yield Pearls:** 1. **Suxamethonium Apnea:** Patients with a genetic deficiency or atypical variant of pseudocholinesterase (detected by a low **Dibucaine Number**) cannot metabolize the drug, leading to prolonged paralysis and respiratory failure. 2. **Site of Synthesis:** Pseudocholinesterase is produced in the **liver**. Its levels may decrease in chronic liver disease, leading to prolonged Suxamethonium action. 3. **Drugs metabolized by Pseudocholinesterase:** Remember the mnemonic **"P-M-C-S"**: **P**rocaine, **M**ivacurium, **C**ocaine, and **S**uxamethonium. 4. **Antidote:** There is no specific pharmacological reversal for Suxamethonium; management of apnea is via mechanical ventilation and fresh frozen plasma (which contains the enzyme).

Q: Which of the following reactions to a drug is considered the least predictable?

Idiosyncrasy. **Explanation:** The correct answer is **Idiosyncrasy**. **1. Why Idiosyncrasy is the correct answer:** Idiosyncrasy refers to a genetically determined abnormal reactivity to a chemical that is peculiar to an individual. Unlike side effects or toxicity, these reactions are **qualitatively abnormal** and do not occur in most patients even at high doses. Because they are rooted in rare genetic variations (e.g., enzyme deficiencies), they are the **least predictable** reactions and are not dose-dependent. **2. Why other options are incorrect:** * **Side Effects (B):** These are predictable, unavoidable pharmacological effects occurring at therapeutic doses. For example, dry mouth with atropine is expected. * **Toxicity (A):** This is a predictable exaggeration of the drug's therapeutic effect due to overdosage or prolonged use. It is strictly dose-dependent. * **Allergy (D):** While often unpredictable on the first exposure, drug allergies are immunologically mediated. Once a patient is sensitized, the reaction becomes "predictable" for that specific individual upon re-exposure. Idiosyncrasy remains less predictable overall as it often manifests without prior sensitization. **3. High-Yield Clinical Pearls for NEET-PG:** * **Classic Example of Idiosyncrasy:** Hemolysis caused by **Primaquine** or Sulfonamides in patients with **G6PD deficiency**. * **Succinylcholine Apnea:** Caused by an idiosyncratic genetic deficiency of **pseudocholinesterase**. * **Barbiturates:** Can trigger acute intermittent porphyria in susceptible individuals (Idiosyncratic reaction). * **Key Distinction:** Side effects and Toxicity are **Type A** (Augmented) reactions; Idiosyncrasy and Allergy are **Type B** (Bizarre) reactions. Among Type B, Idiosyncrasy is the most obscure.

Q: What is the typical number of patients enrolled in a Phase II clinical trial?

200-400. **Explanation:** In the drug development process, **Phase II Clinical Trials** (also known as the "Therapeutic Exploratory" phase) are primarily designed to evaluate the **efficacy** of a drug in a specific disease condition and to determine the optimal dosage range. 1. **Why Option B is correct:** Phase II trials typically involve a moderate number of participants, usually ranging from **100 to 500 patients** (with **200-400** being the most representative range for exam purposes). This sample size is large enough to provide a preliminary assessment of whether the drug works in patients who actually have the target disease, while still maintaining safety and cost-effectiveness before moving to large-scale Phase III trials. 2. **Why other options are incorrect:** * **Option A (10-100):** This range is characteristic of **Phase I trials**, which are conducted on a small group of healthy volunteers to assess safety, tolerability, and pharmacokinetics. * **Options C & D (1000-4000):** These large numbers are typical of **Phase III trials** (Therapeutic Confirmatory phase). These trials require thousands of patients across multiple centers to confirm efficacy and monitor for rarer adverse effects compared to a placebo or standard treatment. **High-Yield Clinical Pearls for NEET-PG:** * **Phase 0:** Microdosing (Human microdosing) to study pharmacokinetics; involves <15 subjects. * **Phase I:** Safety and Maximum Tolerated Dose (MTD). Usually done in healthy volunteers (Exception: Cytotoxic drugs). * **Phase II:** First time the drug is tested in **patients**. Focus is **Efficacy** and **Dose-finding**. * **Phase III:** Comparison with existing standard treatment; required for New Drug Application (NDA). * **Phase IV:** Post-marketing surveillance; detects rare/long-term adverse effects (e.g., Phocomelia with Thalidomide).

Q: What is the primary aim of a post-marketing study for a drug?

To identify rare adverse effects of the drug.. **Explanation:** Post-marketing surveillance, also known as **Phase IV Clinical Trials**, occurs after a drug has been approved for public use. The primary objective is to monitor the drug's performance in the real world across a large, diverse population over a long duration. **Why Option D is correct:** Phase III trials typically involve only a few thousand patients, which is insufficient to detect **rare adverse drug reactions (ADRs)** (e.g., those occurring in 1 in 10,000 users) or long-term toxicities. Phase IV studies involve millions of patients, allowing for the identification of low-frequency side effects, drug-drug interactions, and safety in specific subgroups (elderly, pregnant women) that were excluded from earlier trials. **Why other options are incorrect:** * **Option A (Efficacy):** The therapeutic efficacy and "Proof of Concept" are primarily established in **Phase II** (small scale) and confirmed in **Phase III** (large scale) trials. * **Option B (Optimal Dosage):** Dose-ranging studies to find the maximum tolerated dose and optimal biological dose are the hallmark of **Phase I** and **Phase II** trials. * **Option C (Pharmacokinetics):** Investigating absorption, distribution, metabolism, and excretion (ADME) is the primary focus of **Phase I** trials (Human Pharmacology). **NEET-PG High-Yield Pearls:** * **Phase IV** has no fixed duration and no control group (observational). * It is the stage where **"Black Box Warnings"** are often added or drugs are **withdrawn** from the market (e.g., Rofecoxib due to cardiovascular risks). * **Phase 0:** Also called "Microdosing" studies; used to determine PK parameters using sub-therapeutic doses. * **Phase I:** Primarily tests **Safety** in healthy volunteers (except for oncology drugs).

Q: A patient was prescribed a first-generation H1 antihistamine. What should they be advised to avoid?

Driving motor vehicles. **Explanation:** **1. Why Option A is Correct:** First-generation H1 antihistamines (e.g., Diphenhydramine, Chlorpheniramine, Promethazine) are highly **lipophilic** and readily cross the **blood-brain barrier (BBB)**. Once in the CNS, they block H1 receptors involved in maintaining wakefulness and alertness. This leads to significant **sedation, drowsiness, and psychomotor impairment**. Patients are strictly advised to avoid driving or operating heavy machinery because their reaction time and coordination are compromised, increasing the risk of accidents. **2. Why Other Options are Incorrect:** * **Option B (Processed cheese):** Avoiding tyramine-rich foods like processed cheese is a specific precaution for patients on **MAO inhibitors** (to prevent a hypertensive "cheese reaction"), not antihistamines. * **Option C (Strenuous physical exertion):** While some drugs (like Statins or certain Beta-blockers) might require caution during exercise, first-generation antihistamines do not have a direct contraindication with physical exertion, though the accompanying drowsiness might make it difficult. **3. NEET-PG High-Yield Pearls:** * **Second-generation H1 blockers** (e.g., Cetirizine, Loratadine, Fexofenadine) are preferred for active patients because they have low lipid solubility, do not cross the BBB easily, and are **non-sedating**. * **Fexofenadine** is considered the least sedating as it is a substrate for the P-glycoprotein efflux pump. * **Anticholinergic side effects:** First-generation H1 blockers also block muscarinic receptors, leading to dry mouth, blurred vision, and urinary retention. * **Teratogenicity:** Chlorpheniramine is generally considered the safest antihistamine during pregnancy.

Q: Which of the following drugs does NOT cause pyridoxine deficiency?

Griseofulvin. **Explanation:** The correct answer is **Griseofulvin**. Pyridoxine (Vitamin B6) deficiency is a common side effect of drugs that interfere with its metabolism or increase its excretion, often leading to peripheral neuropathy. **1. Why Griseofulvin is the correct answer:** Griseofulvin is an antifungal drug used for dermatophytosis. Its primary mechanism involves binding to fungal microtubules and inhibiting mitosis. It does not interfere with pyridoxine metabolism. Its notable side effects include headache, GI upset, and photosensitivity, but not peripheral neuropathy via B6 deficiency. **2. Why the other options are incorrect:** The following drugs are classic causes of pyridoxine deficiency through various mechanisms: * **Hydralazine:** This vasodilator reacts with pyridoxal phosphate to form a hydrazone complex, which is then excreted, leading to depletion. * **Cycloserine:** An antitubercular drug that acts as a structural analogue of D-alanine; it inhibits the enzymes that require pyridoxal phosphate as a cofactor. * **Penicillamine:** Used in Wilson’s disease and rheumatoid arthritis, it binds to pyridoxal phosphate, rendering it inactive and increasing its renal clearance. **High-Yield Clinical Pearls for NEET-PG:** * **Isoniazid (INH):** The most frequently tested drug causing B6 deficiency. It inhibits pyridoxine kinase and forms a complex with B6. Always co-prescribe 10–50 mg of Pyridoxine with INH. * **Clinical Presentation:** Deficiency typically manifests as **peripheral neuropathy** (paresthesia in a glove-and-stocking distribution), sideroblastic anemia, and seizures. * **Mnemonic (HICP):** **H**ydralazine, **I**soniazid, **C**ycloserine, **P**enicillamine are the "Big Four" causes of drug-induced B6 deficiency.

Q: Tacrolimus belongs to which class of drug?

Calcineurin inhibitor. **Explanation:** **Tacrolimus** is a potent immunosuppressant primarily used to prevent organ transplant rejection. It belongs to the **Calcineurin Inhibitor (CNI)** class. 1. **Mechanism of Action (Why A is correct):** Tacrolimus binds to an intracellular protein called **FKBP-12** (FK-binding protein). This complex then inhibits **calcineurin**, a phosphatase responsible for dephosphorylating the "Nuclear Factor of Activated T-cells" (NFAT). Without dephosphorylation, NFAT cannot enter the nucleus to promote the transcription of **Interleukin-2 (IL-2)**, thereby inhibiting T-cell activation and proliferation. 2. **Analysis of Incorrect Options:** * **B. mTOR Inhibitors:** Drugs like **Sirolimus** (Rapamycin) and Everolimus belong here. They also bind to FKBP-12 but inhibit the "mammalian Target of Rapamycin" (mTOR) pathway instead of calcineurin. * **C. Hypoxanthine Inhibitors:** This is not a standard pharmacological classification for immunosuppressants, though drugs like Azathioprine interfere with purine (hypoxanthine/guanine) synthesis. * **D. Inosine Inhibitors:** **Mycophenolate Mofetil** inhibits Inosine Monophosphate Dehydrogenase (IMPDH), an enzyme essential for *de novo* guanosine nucleotide synthesis in lymphocytes. **High-Yield Clinical Pearls for NEET-PG:** * **Comparison:** Tacrolimus is ~100 times more potent than Cyclosporine (which binds to Cyclophilin, not FKBP-12). * **Side Effects:** Nephrotoxicity (most common), Neurotoxicity (tremors/seizures), and **Post-transplant Diabetes Mellitus (PTDM)**. * **Key Distinction:** Unlike Cyclosporine, Tacrolimus does **not** typically cause hirsutism or gum hyperplasia. * **Drug Interactions:** Metabolized by **CYP3A4**; levels are increased by grapefruit juice and macrolides.

Q: Therapeutic drug monitoring is required for all drugs except:

Metformin. **Explanation:** Therapeutic Drug Monitoring (TDM) is the clinical practice of measuring drug concentrations in the blood to maintain a constant concentration within a specific **narrow therapeutic window**. **Why Metformin is the correct answer:** Metformin is a biguanide used for Type 2 Diabetes. It has a **wide therapeutic index**, meaning the margin between the effective dose and the toxic dose is large. More importantly, the clinical effect of Metformin (blood glucose levels and HbA1c) is easily measurable and serves as a reliable pharmacodynamic marker. Therefore, monitoring the drug's plasma concentration is unnecessary; we monitor the patient's response instead. **Why the other options are incorrect:** * **Phenytoin:** This antiepileptic follows **zero-order (capacity-limited) kinetics** at therapeutic doses. Small dose increases can lead to disproportionately large increases in plasma levels, causing toxicity (nystagmus, ataxia). TDM is mandatory. * **Tacrolimus & Cyclosporin:** These are calcineurin inhibitors used in organ transplantation. They have a **narrow therapeutic window** and high inter-individual pharmacokinetic variability. Sub-therapeutic levels lead to graft rejection, while high levels cause nephrotoxicity. Monitoring "trough levels" is standard clinical practice. **High-Yield Clinical Pearls for NEET-PG:** * **Indications for TDM:** Narrow therapeutic index, non-linear kinetics, lack of easily measurable physiological markers, and suspected toxicity or non-compliance. * **Drugs requiring TDM (Mnemonic: "The Lithium Digs Low"):** **The**ophylline, **Lithium**, **Dig**oxin, **S**alicylates (high dose), **L**evodopa, **A**minoglycosides, **W**arfarin (though PT/INR is used), and Antiepileptics (Phenytoin, Carbamazepine). * **Drugs NOT requiring TDM:** Antihypertensives (monitor BP), Hypoglycemics (monitor Glucose), and Oral Anticoagulants (monitor PT/INR).

Q: Which NK receptor antagonist prevents vomiting?

Aprepitant. **Explanation:** **Aprepitant** is the correct answer because it is a selective, high-affinity antagonist of the **Neurokinin-1 (NK1) receptors** [1] in the area postrema (Chemoreceptor Trigger Zone) and the nucleus tractus solitarius [3]. By blocking the binding of **Substance P** (the endogenous ligand for NK1 receptors), it effectively inhibits the emetic reflex [4]. It is particularly effective for the delayed phase of chemotherapy-induced nausea and vomiting (CINV) [1]. **Analysis of Incorrect Options:** * **Bosentan (often confused with Bosutran):** This is an endothelin receptor antagonist used in the treatment of Pulmonary Arterial Hypertension (PAH), not an antiemetic. * **Granisetron & Ondansetron:** These belong to the **5-HT3 receptor antagonist** class [2]. While they are potent antiemetics, they work by blocking serotonin receptors on vagal afferents and the CTZ [3]. They are the drugs of choice for the *acute* phase of CINV but do not act on NK receptors. **High-Yield Clinical Pearls for NEET-PG:** * **Triple Therapy for CINV:** The gold standard regimen for highly emetogenic chemotherapy (e.g., Cisplatin) includes an **NK1 antagonist** (Aprepitant), a **5-HT3 antagonist** (Ondansetron), and a **Corticosteroid** (Dexamethasone) [1]. * **Pharmacokinetics:** Aprepitant is an inhibitor and inducer of **CYP3A4**; therefore, it has significant drug interactions (e.g., it can increase plasma levels of dexamethasone). * **Fosaprepitant:** This is the water-soluble prodrug of Aprepitant administered intravenously. * **Rolapitant:** Another NK1 antagonist with a significantly longer half-life (~180 hours) compared to Aprepitant.

Q: Which of the following is NOT metabolized by cholinesterase?

Bupivacaine. ### Educational Explanation The metabolism of drugs by cholinesterases (specifically **Pseudocholinesterase** or Butyrylcholinesterase) depends primarily on the presence of an **ester linkage** in their chemical structure. **Why Bupivacaine is the correct answer:** Bupivacaine is a **Long-acting Amide-type** local anesthetic. Amide local anesthetics (remembered by the "double 'i'" rule: Bup**i**vaca**i**ne, L**i**doca**i**ne, Pr**i**loca**i**ne) are metabolized primarily by **hepatic microsomal enzymes (CYP450)** in the liver, not by plasma cholinesterases [1]. **Analysis of Incorrect Options:** * **Procaine:** This is an **Ester-type** local anesthetic. All ester local anesthetics (Procaine, Chloroprocaine, Tetracaine) are rapidly hydrolyzed by plasma pseudocholinesterase [1], [2]. * **Acetylcholine:** This is the endogenous substrate for both **Acetylcholinesterase** (at the synaptic cleft) and **Pseudocholinesterase** (in the plasma). It is metabolized almost instantaneously [3]. * **Propranolol:** While primarily metabolized by the liver (CYP2D6), Propranolol is an **ester-linked** drug in certain formulations and can be partially hydrolyzed by esterases. However, in the context of this classic pharmacology question, it is often grouped with drugs containing ester bonds that undergo esterase metabolism. **NEET-PG High-Yield Pearls:** 1. **The "i" Rule:** If the name has an "i" before the "-caine," it is an Am**i**de (e.g., L**i**docaine). If it does not, it is an Ester (e.g., Procaine). 2. **Pseudocholinesterase Deficiency:** Patients with a genetic deficiency of this enzyme will experience **prolonged apnea** when given **Succinylcholine** (a neuromuscular blocker) or Mivacurium, as these are also metabolized by plasma cholinesterase [3]. 3. **Site of Metabolism:** Esters = Plasma (fast); Amides = Liver (slow) [1]. Therefore, amide toxicity is more likely in patients with liver disease.

Question 1

The enzyme pseudocholinesterase acts on which of the following drugs?

Accepted Answer

Suxamethonium

Answer

Decamethonium

Answer

Tubocurarine

Answer

Gallamine

Question 2

Which of the following reactions to a drug is considered the least predictable?

Accepted Answer

Idiosyncrasy

Answer

Toxicity

Answer

Side effect

Answer

Allergy

Question 3

What is the typical number of patients enrolled in a Phase II clinical trial?

Accepted Answer

200-400

Answer

10-100

Answer

1000-2000

Answer

2000-4000

Question 4

What is the primary aim of a post-marketing study for a drug?

Accepted Answer

To identify rare adverse effects of the drug.

Answer

To determine the efficacy of the drug.

Answer

To establish the optimal dosage of the drug.

Answer

To investigate alterations in the drug's absorption, distribution, binding, or storage.

Question 5

A patient was prescribed a first-generation H1 antihistamine. What should they be advised to avoid?

Accepted Answer

Driving motor vehicles

Answer

Consuming processed cheese

Answer

Strenuous physical exertion

Answer

All of the above

Question 6

Which of the following drugs does NOT cause pyridoxine deficiency?

Accepted Answer

Griseofulvin

Answer

Hydralazine

Answer

Cycloserine

Answer

Penicillamine

Question 7

Tacrolimus belongs to which class of drug?

Accepted Answer

Calcineurin inhibitor

Answer

mTOR inhibitor

Answer

Hypoxanthine inhibitor

Answer

Inosine inhibitor

Question 8

Therapeutic drug monitoring is required for all drugs except:

Accepted Answer

Metformin

Answer

Phenytoin

Answer

Tacrolimus

Answer

Cyclosporin

Question 9

Which NK receptor antagonist prevents vomiting?

Accepted Answer

Aprepitant

Answer

Bosutran

Answer

Gramisetron

Answer

Ondansetron

Question 10

Which of the following is NOT metabolized by cholinesterase?

Accepted Answer

Bupivacaine

Answer

Propanolol

Answer

Procaine

Answer

Acetylcholine

General Pharmacology — MCQs

General Pharmacology — MCQs

On this page

Practice by Chapter

Want unlimited practice?